chinatown1980,
If all SOC evented as per Dr. Linda Liau slide during presentation, how is that consistent with no treatment effect when 83 treatment patients had not yet evented? Secondly, GBM requires a slow acting immune response to prevent massive infiltration of immune cells leading to swelling and trauma to the brain. This has already been discussed ad nauseum. If you can't remember things very well then I suggest you write this down and repost this as a reminder before each and any of your future comments.
DC therapy combined with checkpoint inhibitors with reduced tumor burden after surgery or potentially at early detected recurrence, especially after an additional resection appears to have a strong to best possibility for positive benefit. This is why Dr. Prins would focus on combos for GBM even if some patients may not require them for positive benefit. The patient population able to gain maximum benefit from treatment increases with DC/checkpoint combos so focusing on combos, even if individual treatments find benefit to a lesser degree on their own, makes sense. I think you already know this but like I said, feel free to repost this as a header at the beginning of each of your future posts as a convenient reminder. Best wishes.
Market Data 
Markets 
AI
